Extended remdesivir with nirmatrelvir/ritonavir for persistent COVID-19 in immunocompromised patients
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial studies a longer course of remdesivir combined with nirmatrelvir/ritonavir (Paxlovid) for immunocompromised patients who have persistent COVID-19. The goal is to see if this combination helps clear the virus better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have received B-cell depletion therapy or bendamustine within the last 6 months.
- You have a confirmed SARS-CoV-2 (COVID-19) infection.
- Your symptoms started within the last 72 hours.
- You are not currently on a ventilator.
- You have not used other COVID-19 treatments in the past 2 weeks, unless it was remdesivir or nirmatrelvir/ritonavir started within 24 hours.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether an optimized antiviral treatment can help people with weakened immune systems who have COVID-19. It aims to find the best way to treat them to prevent severe illness.
This study tests the best combination and timing of antiviral medicines for people with COVID-19 who have weakened immune systems. It aims to improve outcomes in people with mild to moderate illness.
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
This trial tests a new drug, ratutrelvir, for people with mild to moderate COVID-19. It aims to find a safe and effective dose to help you feel better faster.
This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.